Coeptis Therapeutics (COEP) Competitors $11.63 -0.28 (-2.35%) Closing price 04:00 PM EasternExtended Trading$12.06 +0.43 (+3.74%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. LYEL, IMRX, LIMN, GLSI, NKTX, THTX, IKT, FATE, TNYA, and CGENShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Lyell Immunopharma (LYEL), Immuneering (IMRX), Liminatus Pharma (LIMN), Greenwich LifeSciences (GLSI), Nkarta (NKTX), Theratechnologies (THTX), Inhibikase Therapeutics (IKT), Fate Therapeutics (FATE), Tenaya Therapeutics (TNYA), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Lyell Immunopharma Immuneering Liminatus Pharma Greenwich LifeSciences Nkarta Theratechnologies Inhibikase Therapeutics Fate Therapeutics Tenaya Therapeutics Compugen Coeptis Therapeutics (NASDAQ:COEP) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends. Which has more volatility & risk, COEP or LYEL? Coeptis Therapeutics has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Is COEP or LYEL more profitable? Coeptis Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -514,649.22%. Lyell Immunopharma's return on equity of -73.66% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -282.39% -127.23% Lyell Immunopharma -514,649.22%-73.66%-60.99% Does the media prefer COEP or LYEL? In the previous week, Lyell Immunopharma had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Lyell Immunopharma and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.28 beat Lyell Immunopharma's score of 0.94 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, COEP or LYEL? Coeptis Therapeutics has higher earnings, but lower revenue than Lyell Immunopharma. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.01Lyell Immunopharma$60K3,065.67-$342.99M-$25.00-0.50 Do insiders and institutionals believe in COEP or LYEL? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 22.3% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate COEP or LYEL? Lyell Immunopharma has a consensus target price of $15.00, indicating a potential upside of 20.77%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SummaryLyell Immunopharma beats Coeptis Therapeutics on 8 of the 13 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.85M$3.03B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A21.1828.1120.03Price / SalesN/A339.44461.57200.15Price / CashN/A43.2336.5559.01Price / Book7.228.368.655.90Net Income-$10.88M-$55.19M$3.25B$258.66M7 Day Performance8.90%5.89%4.20%2.23%1 Month Performance41.83%17.63%10.82%12.76%1 Year Performance117.30%5.09%34.70%19.36% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.6865 of 5 stars$11.63-2.4%N/A+117.3%$41.85MN/A0.002Positive NewsGap UpLYELLyell Immunopharma2.5117 of 5 stars$10.28+8.3%$15.00+45.9%-67.7%$152.25M$60K-0.41270News CoverageGap UpIMRXImmuneering3.1424 of 5 stars$4.22-0.5%$13.25+214.0%+247.8%$151.88M$320K-2.1560LIMNLiminatus PharmaN/A$5.78+3.6%N/AN/A$150.34MN/A0.00N/ANews CoverageGap DownHigh Trading VolumeGLSIGreenwich LifeSciences2.2011 of 5 stars$11.14-5.3%$39.00+250.1%-26.1%$148.94MN/A-8.843High Trading VolumeNKTXNkarta1.7718 of 5 stars$2.08+8.3%$14.33+589.1%-67.8%$147.60MN/A-1.38140THTXTheratechnologiesN/A$3.16+0.6%N/A+117.2%$145.30M$84.38M-16.63140IKTInhibikase Therapeutics1.484 of 5 stars$1.93+2.7%$6.50+236.8%+12.8%$143.48MN/A-0.726News CoverageFATEFate Therapeutics3.6783 of 5 stars$1.24+7.8%$3.83+209.1%-75.9%$142.10M$13.63M-0.83550TNYATenaya Therapeutics3.8258 of 5 stars$0.85-0.7%$6.25+634.7%-77.2%$138.38MN/A-0.73110Positive NewsCGENCompugen1.4344 of 5 stars$1.55+2.6%$4.00+158.1%-12.0%$138.32M$27.86M-9.6970 Related Companies and Tools Related Companies Lyell Immunopharma Alternatives Immuneering Alternatives Liminatus Pharma Alternatives Greenwich LifeSciences Alternatives Nkarta Alternatives Theratechnologies Alternatives Inhibikase Therapeutics Alternatives Fate Therapeutics Alternatives Tenaya Therapeutics Alternatives Compugen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
